Avid Bioservices, Inc.

CDMO

US05368M1062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
7.42 ^USD	-3.64%		+3.92%	+14.15%

Jul. 02	Avid Bioservices Fiscal Q4 Loss Widens, Revenue Increases; Fiscal 2025 Revenue Outlook Set	MT
Jul. 02	Transcript : Avid Bioservices, Inc., Q4 2024 Earnings Call, Jul 02, 2024

Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell Microcap Value Index

July 30, 2024

Latest news about Avid Bioservices, Inc.

Avid Bioservices Fiscal Q4 Loss Widens, Revenue Increases; Fiscal 2025 Revenue Outlook Set	Jul. 02	MT
Transcript : Avid Bioservices, Inc., Q4 2024 Earnings Call, Jul 02, 2024	Jul. 02
Avid Bioservices, Inc. Reports Earnings Results for the Full Year Ended April 30, 2024	Jul. 02	CI
Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025	Jul. 02	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell 2500 Value Index	Jun. 30	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell 3000 Value Index	Jun. 30	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell 2000 Value Index	Jun. 30	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell Microcap Value Index	Jun. 30	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell 3000E Value Index	Jun. 30	CI
RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	Apr. 30	MT
Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024	Apr. 29
Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Apr. 24	CI
North American Morning Briefing : Stock Futures -2-	Apr. 19	DJ
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	Apr. 05	DJ
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Avid Bioservices Receives Nasdaq Noncompliance Notice	Mar. 20	MT
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	Mar. 15	DJ
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating	Mar. 11	MT
Avid Bioservices Prices $160 Million Convertible Notes Offering; Shares Slump	Mar. 07	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Buoyed by Powell's Comments	Mar. 07	MT
Top Premarket Decliners	Mar. 07	MT
Avid Bioservices Shares Slide After Pricing Private Placement of Convertible Notes	Mar. 07	DJ
Avid Bioservices Prices $160 Million Convertible Notes Offering	Mar. 07	MT
Avid Bioservices Preliminary Fiscal Q3 Revenue Falls 11%; $160 Million Private Placement of Notes Set; Shares Slump	Mar. 06	MT

Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.

Sector

Pharmaceuticals

Calendar

2024-09-04 - Q1 2025 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Avid Bioservices, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.42 USD

Average target price

12.5 USD

Spread / Average Target

+68.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AVID BIOSERVICES, INC.	+14.15%	472M
CSL LIMITED	+4.57%	97.7B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.43B
BIOGEN INC.	-12.80%	32.85B
UCB	+80.99%	29.33B
BIOMARIN PHARMACEUTICAL INC.	-15.53%	15.47B
INCYTE CORPORATION	-8.70%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	11.51B
ALTEOGEN INC.	+183.25%	10.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-55.41%	8.97B

Biopharmaceuticals